Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

0.6503 -0.0202 (-3.01%)
Streaming Delayed Price Updated: 2:37 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherap

< Previous 1 2 3 4 5 6 7 8 Next >
Atara Biotherapeutics's Earnings Outlook
Via Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
3 Doomed Biotech Stocks Destined for Disaster
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures. 
Via InvestorPlace
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
A Preview Of Atara Biotherapeutics's Earnings
Via Benzinga
Looking Into Atara Biotherapeutics's Return On Capital Employed
Via Benzinga
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios. 
Via InvestorPlace
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
Why Bed Bath & Beyond Fell Almost 30%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.